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Objective: To compare the effectiveness and convenience of a pen device for the self-administration of follitropin β with a conventional syringe 
delivering follitropin β solution in patients undergoing IVF-ET. 
Methods: GnRH agonist long protocol was used for controlled ovarian stimulation (COS) in all subjects. A total of 100 patients were random-
ized into the pen device group or the conventional syringe group on the first day of COS. Local tolerance reactions were assessed within 5 min-
utes, at 1 hour and at 3 hours after each injection. On the day of hCG injection, patients were asked to rate their overall pain and convenience 
experienced with self-injection on a visual anlaogue scale (VAS). 
Results: There were no differences in patients’ characteristics between the two groups. The duration of COS was significantly shorter in the pen 
device group than in the conventional syringe group. Patients included in the pen device group needed a significantly smaller amount of folli-
tropin β. However, no differences between the two groups were found in IVF results and pregnancy outcome. The incidence of local pain within 
5 minutes, at 1 hour and at 3 hours after the injection was significantly lower in the pen device group. VAS scores indicated that injections using 
the pen device were significantly less painful and more convenient. 
Conclusion: The pen device for self-administration of follitropin β is less painful, safer and more convenient for the patients, and can be more 
effective because of the shorter duration and smaller dose of follitropin β when compared with the conventional syringe. 
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Introduction 
Urinary FSH had been replaced by recombinant human FSH (rhFSH) 
because rhFSH has a lower risk of immunogenicity and infection than 
that of the urinary products. Recombinant products are highly pure 
(>99%), and indeed, no antibodies to FSH have been detected in se-
rum samples from patients who have injected rhFSH. Therefore, the 
use of this recombinant product has resulted in more efficient and 
predictable ovulation induction or controlled ovarian stimulation 
(COS). Additionally, rhFSH has been shown to be suitable for subcu-
taneous (SC) administration and SC injections allow for easy self-ad-
ministration by patients [1,2].
RhFSH was first available as a freeze-dried lyophilized powder, which 
had to be dissolved in water for injection before administration. Re-
cently, rhFSH has been made available as a premixed ready-to-use 
solution and this product has been considered more “patient friend-
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ly”. A subsequent advance in patient-friendly regimens is the devel-
opment of rhFSH solution, which is stored in cartridge form for ad-
ministration with a pen device. This multiple-use pen device for SC 
self-administration of rhFSH, which is approved under the brand name 
Puregon Pen has been available in Europe since 2002. This pen injec-
tor is an adapted insulin pen, which has been shown to be better ac-
cepted by diabetes patients in comparison with conventional syring-
es, as it provides for an easier, safer, more accurate and more discrete 
insulin injection [3].
This study was performed to compare the effectiveness and conve-
nience of a pen device for the self-administration of rhFSH (follitropin 
β) with a conventional syringe delivering rhFSH solution in patients 
undergoing COS for IVF-ET.
Methods
This study was a prospective, randomized, single center, group 
comparative study. A total of 100 infertile Korean women who were 
scheduled for IVF-ET with or without ICSI were enrolled in this study 
and they were divided into the pen device group or the conventional 
syringe group by a computer-generated randomization list using 
random numbers on the first day of COS. The patients were 20-39 
years of age at the time of screening, and had normal ovulatory cy-
cles (24-35 days in length), had a body mass index (BMI) between 18 
and 29 kg/m², and were willing to self-inject rhFSH. 
Patients who had a history of current endocrine abnormalities, such 
as polycystic ovary syndrome, hyperprolactinemia, and a previous 
history of IVF-ET in which less than three oocytes were retrieved were 
excluded in this study. Patients who had any abnormalities that would 
interfere with adequate stimulation, previous hospitalization due to 
severe ovarian hyperstimulation syndrome (OHSS), history of previ-
ous (within 12 months) or current abuse of alcohol or drugs were also 
excluded from this study. 
All patients received the same COS regimen, GnRH agonist luteal 
long protocol using triptorelin acetate (Decapeptyl; Ferring, Malmo, 
Sweden). After an absence of ovarian activity was confirmed by trans-
vaginal ultrasound and/or serum estradiol levels after the adminis-
tration of triptorelin acetate for at least 2 weeks, ovarian stimulation 
with rhFSH was carried out in both groups, starting with 200 or 250 
IU follitropin β. 
On the first day of ovarian stimulation, all subjects were randomized 
to self-administer rhFSH using a pen device (Puregon Pen; Organon, 
Oss, Netherland) equipped with a needle sized 29 G×13 mm or a 
conventional syringe equipped with a needle sized 25 G×16 mm by 
a computer generated randomization list using random numbers. 
On the first day of ovarian stimulation, patients were instructed how 
to self-inject subcutaneously into the abdominal wall around the 
umbilicus with a pen device or a conventional syringe and super-
vised in order to ensure correct self-injection.  
After stimulation day 5, the dose of follitropin β was adjusted ac-
cording to the individual ovarian response monitored by transvagi-
nal ultrasound examinations. When one leading follicle reached 18 
mm in diameter or 2 or more follicles reached 17 mm, oocyte matu-
ration was triggered with 10,000 IU of hCG (Pregnyl; Organon) ad-
ministered as a single intramuscular injection. Transvaginal ultra-
sound-guided oocyte retrieval was performed 36 hours after hCG 
administration. Embryos were transferred 3 days after oocyte retriev-
al. Luteal support was provided by administering 90 mg of vaginal 
progesterone gel (Crinone gel 8%; Serono SA, Geneva, Switzerland) 
once daily from the day of oocyte retrieval. Serum β-hCG levels were 
measured 11 or 12 days after embryo transfer. Pregnancies were 
confirmed by rising serum β-hCG concentrations and transvaginal 
ultrasonographic evidence of a gestational sac. If pregnancy was di-
agnosed, vaginal progesterone administration was continued for an-
other 5 to 7 weeks. Clinical pregnancy was defined as the presence 
of a gestational sac by ultrasonography, while the miscarriage rate 
per clinical pregnancy was defined as the proportion of patients who 
failed to continue development before reaching 20 weeks of gesta-
tion among all clinical pregnancies.
1. Local tolerance and convenience assessment 
After every injection of follitropin β, the severity of local tolerance 
symptoms was assessed by the patients themselves and recorded in 
a ‘local tolerance diary book’, within 5 minutes, at 1 hour and at 3 hours 
after injection. Local tolerance items scored were pain, redness, itch-
ing, bruising and swelling. The severity of symptoms was scored as 
none, mild, moderate, or severe. The incidence of each local tolerance 
item was compared between the pen device group and the conven-
tional syringe group. Incidence indicates the percentage of subjects 
with mild, moderate or severe local tolerance symptoms for each 
item at each assessment. Additionally, on the day of hCG administra-
tion, patients were asked to rate their overall pain and convenience 
experienced with this self-injection method on a visual anlaogue 
scale (VAS). The VAS ranged from 0 (severe pain, not convenient) to 
10 (no pain, very convenient). 
2. Statistical analysis
The mean value was expressed as the mean±standard deviation 
(SD). A Student’s t-test was used to compare the mean values. The 
chi-square test and Fisher’s exact test were used for the comparison 
of fractions. Statistical significance was defined as p<0.05. All analy-
ses were performed using SPSS ver. 11.0 (SPSS Inc., Chicago, IL, USA). www.eCERM.org
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Results
There were no differences in the age of patients and spouses, BMI, 
infertility duration, the rate of the patients with primary infertility, 
basal endocrine profile and indications for IVF/ICSI between the two 
groups (Table 1). The duration of COS with rhFSH was significantly 
shorter in the pen device group than in the conventional syringe 
group (p<0.05). Patients included in the pen device group needed 
significantly less rhFSH, with 2,091.0±318.8 IU compared with 
2,248.0±405.0 IU in the conventional syringe group (p<0.05). How-
ever, no differences were found between the two groups in the num-
bers of oocytes retrieved, mature oocytes, fertilized oocytes, grade I/
II embryos, frozen embryos and transferred embryos. Also, there were 
no differences between the two groups in the clinical pregnancy rate, 
implantation rate, miscarriage rate, multiple pregnancy rate and the 
incidence of severe OHSS (Table 2).
The incidence of local pain within 5 minutes after injection was sig-
nificantly lower in the pen device group (p<0.05). The incidence of 
local redness within 5 minutes after injection was also significantly 
lower in the pen device group (p<0.05). The incidence of local pain 
at 1 hour and 3 hours after injection were significantly lower in the 
pen device group (p<0.05, p<0.05) (Figure 1). The mean overall pain 
score assessed by VAS was significantly higher in the pen device group 
than in the conventional syringe group (9.3±0.9 vs. 8.6±1.4; p<0.01), 
and the convenience score was also significantly higher in the pen 
device group (9.4±0.7 vs. 8.0±1.6; p<0.001). 
Discussion
The introduction of a pen device for the administration of recombi-
nant insulin in the treatment of diabetes resulted in significant im-
provements for patients in terms of local discomfort, accurate dosing 
and convenience to the patients [4-6]. The development of the pen 
device made it possible for patients to self-inject medication, reduce 
the number of visits to the clinic and administer accurate doses of 
drugs. A similar pen device for the injection of gonadotropin was 
deemed necessary for the convenience and effectiveness of the pa-
tients. A study by Voortman et al. [7] demonstrated that injections of 
similar amounts of follitropin β using either a dissolved cake with a 
conventional syringe or a ready-for-use solution with a pen device 
were bio-equivalent, after correction for injection losses by weighing 
the amount injected with a normal syringe. A difference of approxi-
mately 18% was found between serum FSH concentrations obtained 
using the two formulations, which was caused by differences between 
the anticipated volume and the actual volume injected with the nor-
mal syringe [7]. Another study showed that follitropin β administered 
with a pen device is not only well tolerated but also more efficacious 
with respect to ovarian stimulation outcome when compared with 
the conventional syringe [8]. In our study, the number of administra-
Table 1. Patients’ characteristics
Pen Syringe p-value
No. of patients  50 50
Patients’ age (yr) 33.2±3.5 33.0±3.5 NS
Husbands’ age (yr) 37.8±6.2 38.2±5.9 NS
Infertility duration (yr) 3.4±2.3 3.2±1.9 NS
Patients with primary infertility 16 (32.0) 18 (36.0) NS
BMI (kg/m²) 25.6±2.5 25.5±2.4 NS
Endocrine profile
Basal FSH (mIU/mL) 6.2±1.4 6.0±1.3 NS
Basal LH (mIU/mL) 5.4±1.5 5.3±1.6 NS
T (ng/mL) 0.3±0.1 0.3±0.1 NS
Free T (pg/mL) 0.5±0.2 0.4±0.2 NS
SHBG (nmol/L) 52.4±12.4 50.8±13.3 NS
Estradiol (pg/mL) 29.8±8.4 29.2±9.6 NS
Prolactin (ng/mL) 13.4±3.8 14.3±3.5 NS
Indications
Tubal/peritoneal factor  22 (44.0) 21 (42.0) NS
Male factor  16 (32.0) 18 (36.0) NS
Unexplained 12 (24.0) 11 (22.0) NS
Values are presented as mean±SD or number (%).
NS, not significant; BMI, body mass index; FSH, follicle stimulating 
hormone; LH, luteinizing; T, testosterone; SHBG, sex hormone bind-
ing globulin.
Table 2. Comparison of controlled ovarian stimulation results and 
IVF outcome
Pen Syringe p-value
No. of cycles 50 50
No. of ICSI cycle 15 (30.0) 16 (32.0) NS
Duration of COS (day) 8.7±1.1 9.3±1.3 p<0.05
Total dose of rhFSH (IU) 2,091.0±318.8 2,248.0±405.0 p<0.05
No. of oocytes retrieved 9.8±3.0 9.6±2.7 NS
No. of MII oocytes 8.9±3.0 8.7±2.8 NS
No. of fertilized oocytes 8.8±2.0 8.6±2.8 NS
No. of grade I, II oocytes 3.2±1.5 2.9±1.3 NS
No. of frozen embryos 1.7±1.3 1.5±1.1 NS
No. of embryo transferred 2.9±0.3 3.0±0.3 NS
Clinical pregnancy rate 17/50 (34.0) 18/50 (36.0) NS
Implantation rate 19/145 (13.1) 20/150 (13.3) NS
Miscarriage rate 4/17 (23.5) 4/18 (22.2) NS
Multiple pregnancy rate 2/17 (11.8) 2/18 (11.1) NS
Incidence of severe OHSS 1/50 (2) 2/50 (4) NS
Values are presented as number (%) or mean±SD.
ICSI, intracytoplasmic sperm injection; NS, not significant; COS, con-
trolled ovarian stimulation; rhFSH, recombinant human follicle stim-
ulating hormone; MII, metaphase II; OHSS, ovarian hyperstimulation 
syndrome.  doi: 10.5653/cerm.2011.38.1.37
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tion days and amount of follitropin β required for COS were signifi-
cantly reduced in the pen device group over those in the conven-
tional syringe group. These results suggest that the difference be-
tween the anticipated volume and the actual volume injected was 
higher in the conventional syringe group and that an administration 
of rhFSH by a pen device reduced injection losses. 
A previous study showed that injection pain is experienced less fre-
quently when follitropin β is administered by a pen device than when 
follitropin α is administered with a conventional syringe [9]. In this 
study, the reason the local pain at the injection site was lower in the 
pen device group may have been that the pen device was equipped 
with a finer and shorter needle and injected a smaller volume of 
rhFSH [9]. In our study, patients also experienced local pain less fre-
quently after injection when they used the pen device for injections. 
Overall pain assessed by VAS was also significantly lower in the pen 
device group than in the syringe group. 
None of the patients withdrew from our study because of the pain 
or other side effects. In addition, the incidence of severe OHSS was 
comparable between the two groups. Therefore, the pen device de-
livering rhFSH is judged to be at least as safe as the conventional sy-
ringe. Moreover, the present study demonstrated that the pen device 
is more convenient and easy to handle, when compared with the 
conventional syringe. The pen device delivering follitropin β permits 
accurate titration of rhFSH doses in increments of 25 IU. Individual-
ized treatment for COS was therefore possible at the minimal effec-
tive dose.
In conclusion, the pen device for self-administration of follitropin β 
is safe, less painful and more convenient for patients undergoing COS, 
and can be more effective because of the shorter duration and small-
er dose of follitropin β, when compared with a conventional syringe. 
A reduction of painful injections and the treatment period, and the 
convenient administration of rhFSH can make IVF treatment easier 
and more patient-friendly.  
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